Apthera, Inc. Announces Phase III and Commercial Drug Formulation for NeuVax(TM)
12/9/2008 8:33:18 AM
SCOTTSDALE, AZ--(Marketwire - December 09, 2008) - Apthera, Inc., a biotechnology company focused on peptide-based cancer immunotherapy, today announced that it has determined to go forward with a lyophilized form of the E75 peptide component of its NeuVax product. This commercially viable formulation will provide the Company a stable drug product to conduct worldwide Phase III clinical trials and prepare for commercial sales.
comments powered by